Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90B1 | P14625 | 18/20 | 0.70 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.70 |
| ▸ | TRAP1 | Q12931 | 5/20 | 0.70 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16487064 | 1.00 | HSP90B1 (0.70) | HSP90B1HSP90AA1TRAP1HSP90AB1ERBB2 | |
| SCHEMBL17890363 | 1.00 | HSP90B1 (0.70) | HSP90B1HSP90AA1TRAP1HSP90AB1ERBB2 | |
| SCHEMBL17890350 | 0.95 | HSP90B1 (0.80) | HSP90B1HSP90AA1TRAP1HSP90AB1ERBB2 | |
| SCHEMBL16486825 | 0.95 | HSP90B1 (0.80) | HSP90B1HSP90AA1TRAP1HSP90AB1ERBB2 | |
| SCHEMBL17890346 | 0.95 | HSP90B1 (0.80) | HSP90B1HSP90AA1TRAP1HSP90AB1ERBB2 | |
| SCHEMBL16487136 | 0.88 | HSP90B1 (0.89) | HSP90B1HSP90AA1TRAP1HSP90AB1ERBB2 | |
| SCHEMBL16486885 | 0.84 | HSP90B1 (0.66) | HSP90B1HSP90AA1TRAP1HSP90AB1 | |
| SCHEMBL29358958 | 0.83 | HSP90B1 (1.00) | HSP90B1HSP90AA1TRAP1HSP90AB1ERBB2 | |
| SCHEMBL16487210 | 0.83 | HSP90B1 (1.00) | HSP90B1HSP90AA1TRAP1HSP90AB1ERBB2 | |
| SCHEMBL21385685 | 0.82 | HSP90B1 (0.64) | HSP90B1HSP90AA1TRAP1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-04-14 | — | — | US | disclosed |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-20 | — | — | US | disclosed |
| US-11267816-B2 | Selective Grp94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2021263194-A1 | INHIBITION OF N-GLYCOSYLATED GRP94 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-12-30 | — | — | WO | disclosed |
| CN-105899503-B | Selective GRP94 inhibitors and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2020-08-18 | — | — | CN | disclosed |
| US-20200102312-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2020-04-02 | — | — | US | disclosed |
| US-20200102312-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2020-04-02 | — | — | US | disclosed |
| US-10421758-B2 | Selective Grp94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421758-B2 | Selective Grp94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-09-24 | — | — | US | disclosed |
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2016-07-07 | — | — | US | disclosed |
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2016-07-07 | — | — | US | disclosed |
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | HSP90B1 1/4885HSP90AA1 9/4885TRAP1 15/4885 |
| US-10421758-B2 | Selective Grp94 inhibitors and uses thereof | HSP90B1, HSP90AB2P, HSPE1 | HSP90B1 1/4885HSP90AA1 9/4885TRAP1 15/4885 |
| US-11267816-B2 | Selective Grp94 inhibitors and uses thereof | HSP90B1, HSP90AB2P, HSPE1 | HSP90B1 1/4885HSP90AA1 9/4885TRAP1 15/4885 |
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | GRPR, HSPB1, HSP90AB2P | HSP90B1 12/4885HSP90AA1 14/4885TRAP1 79/4885 |
| US-20200102312-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | HSP90B1 1/4885HSP90AA1 9/4885TRAP1 15/4885 |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | HSP90B1 1/4885HSP90AA1 9/4885TRAP1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.